RY8 — Rongyu Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareMicro Cap

Annual income statement for Rongyu Pharmaceuticals, fiscal year end - March 31st, AUD millions except per share, conversion factor applied.

	2015 March 31st	2016 March 31st	2017 March 31st
Period Length:	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS
Standards:	AAS	AAS	AAS
Status:	Final	Final	Final
Revenue
Total Revenue	41.5	62.3	71.4
Cost of Revenue
Gross Profit	18	27.6	30.2
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	25.7	38.2	45.7
Operating Profit	15.8	24.1	25.8
Net Income Before Taxes	15.8	24.1	25.8
Provision for Income Taxes
Net Income After Taxes	11.9	18.1	19.3
Net Income Before Extraordinary Items
Net Income	11.9	18.1	19.3
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	11.9	18.1	19.3
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.03	0.045	0.048
Dividends per Share